SPTA45: Key Regulator of Cell Growth and Differentiation (G149643)

Target Name: SPATA45

NCBI ID: G149643

SPATA45

SPTA45: Key Regulator of Cell Growth and Differentiation

SPATA45 is a protein that is expressed in various tissues of the human body, including the nervous system, endocrine system, and immune system. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

SPATA45 is a member of the SPT (secretory phospholipase T) family, which is a group of enzymes that are involved in the production of phospholipids, which are important components of cell membranes. These enzymes are involved in a wide range of cellular processes, including the regulation of signaling pathways, cell survival, and the transport of molecules across cell membranes.

SPTA45 is a 45kDa protein that is expressed in various tissues of the human body. It is highly conserved, with a sequence of 45 amino acids that is highly conserved across different species. SPTA45 is predominantly expressed in the brain, with lower levels of expression found in other tissues such as the heart, pancreas, and skin.

SPTA45 is involved in a number of cellular processes that are important for normal brain function. For example, it is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. SPTA45 has been shown to play a role in the regulation of synaptic plasticity, with studies showing that it is involved in the formation of new neurons in the brain and that it promotes the survival of existing neurons.

SPTA45 is also involved in the regulation of neurodegenerative disorders. neurodegenerative disorders are a group of diseases that are characterized by the progressive loss of neural cells and their associated structures. These disorders include Alzheimer's disease, Parkinson's disease, and Huntington's disease. SPTA45 has been shown to be involved in the development and progression of neurodegenerative disorders, with studies showing that it is expressed in the brains of individuals with these disorders and that it is involved in the regulation of neurodegeneration.

SPTA45 is also a potential drug target for the treatment of cancer. Cancer is a leading cause of death worldwide, and there is a strong need for new treatments to address this devastating disease. SPTA45 has been shown to be involved in the regulation of cell growth and division, which are important processes that are involved in the development and progression of cancer. Therefore, SPTA45 is a potential target for the development of anti-cancer drugs.

In addition to its potential as a drug target, SPTA45 is also a potential biomarker for a number of diseases. As mentioned above, SPTA45 is involved in the regulation of various cellular processes that are important for normal brain function. Therefore, it is a potential biomarker for a number of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

In conclusion, SPTA45 is a protein that is involved in a wide range of cellular processes that are important for normal brain function. It is a potential drug target for the treatment of cancer and a potential biomarker for a number of diseases. Further research is needed to fully understand the role of SPTA45 in these processes and to develop new treatments for these diseases.

Protein Name: Spermatogenesis Associated 45

The "SPATA45 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA45 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets